FGF21 has also been shown to suppress sugar preference in animals(32,52,53), while treatment with an FGF21 analogue reduced energy intake and preference for sweet foods in humans with overweight or obesity(33). Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.